284 related articles for article (PubMed ID: 15667909)
1. Rifaximin--a novel antimicrobial for enteric infections.
Huang DB; DuPont HL
J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
Gerard L; Garey KW; DuPont HL
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
Adachi JA; DuPont HL
Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
[TBL] [Abstract][Full Text] [Related]
4. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.
DuPont HL; Jiang ZD
Clin Microbiol Infect; 2004 Nov; 10(11):1009-11. PubMed ID: 15522005
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin: a nonabsorbed oral antibiotic.
Baker DE
Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
[TBL] [Abstract][Full Text] [Related]
6. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.
Infante RM; Ericsson CD; Jiang ZD; Ke S; Steffen R; Riopel L; Sack DA; DuPont HL
Clin Gastroenterol Hepatol; 2004 Feb; 2(2):135-8. PubMed ID: 15017618
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
Taylor DN; Bourgeois AL; Ericsson CD; Steffen R; Jiang ZD; Halpern J; Haake R; Dupont HL
Am J Trop Med Hyg; 2006 Jun; 74(6):1060-6. PubMed ID: 16760520
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.
Scarpignato C; Pelosini I
Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748
[TBL] [Abstract][Full Text] [Related]
9. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.
Koo HL; DuPont HL
Curr Opin Gastroenterol; 2010 Jan; 26(1):17-25. PubMed ID: 19881343
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Cottreau J; Baker SF; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
[TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.
Ruiz J; Mensa L; O'Callaghan C; Pons MJ; González A; Vila J; Gascón J
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):473-5. PubMed ID: 17889485
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.
DuPont HL; Jiang ZD; Okhuysen PC; Ericsson CD; de la Cabada FJ; Ke S; DuPont MW; Martinez-Sandoval F
Ann Intern Med; 2005 May; 142(10):805-12. PubMed ID: 15897530
[TBL] [Abstract][Full Text] [Related]
15. Therapy of travelers' diarrhea with rifaximin on various continents.
Steffen R; Sack DA; Riopel L; Jiang ZD; Stürchler M; Ericsson CD; Lowe B; Waiyaki P; White M; DuPont HL
Am J Gastroenterol; 2003 May; 98(5):1073-8. PubMed ID: 12809830
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
Williams R; Bass N
Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin pharmacology and clinical implications.
Ojetti V; Lauritano EC; Barbaro F; Migneco A; Ainora ME; Fontana L; Gabrielli M; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):675-82. PubMed ID: 19442033
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.
DuPont HL; Ericsson CD; Mathewson JJ; Palazzini E; DuPont MW; Jiang ZD; Mosavi A; de la Cabada FJ
Digestion; 1998; 59(6):708-14. PubMed ID: 9813398
[TBL] [Abstract][Full Text] [Related]
19. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.
Brigidi P; Swennen E; Rizzello F; Bozzolasco M; Matteuzzi D
J Chemother; 2002 Jun; 14(3):290-5. PubMed ID: 12120885
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin treatment of pathogen-negative travelers' diarrhea.
DuPont HL; Haake R; Taylor DN; Ericsson CD; Jiang ZD; Okhuysen PC; Steffen R
J Travel Med; 2007; 14(1):16-9. PubMed ID: 17241249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]